BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M, Chaubert P, Macdonald HR, Romero P, Cerottini J, Speiser DE. Naturally Acquired MAGE-A10- and SSX-2-Specific CD8 + T Cell Responses in Patients with Hepatocellular Carcinoma. J Immunol 2005;174:1709-16. [DOI: 10.4049/jimmunol.174.3.1709] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Fatourou EM, Koskinas JS. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. Expert Review of Anticancer Therapy 2014;9:1499-510. [DOI: 10.1586/era.09.103] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
2 Zajac P, Schultz-Thater E, Tornillo L, Sadowski C, Trella E, Mengus C, Iezzi G, Spagnoli GC. MAGE-A Antigens and Cancer Immunotherapy. Front Med (Lausanne) 2017;4:18. [PMID: 28337438 DOI: 10.3389/fmed.2017.00018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
3 Forghanifard MM, Rad A, Farshchian M, Khaleghizadeh M, Gholamin M, Moghbeli M, Abbaszadegan MR. TWIST1 upregulates the MAGEA4 oncogene: TWIST1 UPREGULATES MAGEA4. Mol Carcinog 2017;56:877-85. [DOI: 10.1002/mc.22541] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
4 Abate-Daga D, Speiser DE, Chinnasamy N, Zheng Z, Xu H, Feldman SA, Rosenberg SA, Morgan RA. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer. PLoS One 2014;9:e93321. [PMID: 24681846 DOI: 10.1371/journal.pone.0093321] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
5 Zerbini A, Pilli M, Ferrari C, Missale G. Is there a role for immunotherapy in hepatocellular carcinoma? Dig Liver Dis 2006;38:221-5. [PMID: 16461021 DOI: 10.1016/j.dld.2005.12.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
6 Breous E, Thimme R. Potential of immunotherapy for hepatocellular carcinoma. Journal of Hepatology 2011;54:830-4. [DOI: 10.1016/j.jhep.2010.10.013] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 6.0] [Reference Citation Analysis]
7 Mizukoshi E, Kaneko S. Immune cell therapy for hepatocellular carcinoma. J Hematol Oncol 2019;12:52. [PMID: 31142330 DOI: 10.1186/s13045-019-0742-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
8 Ormandy LA, Färber A, Cantz T, Petrykowska S, Wedemeyer H, Hörning M, Lehner F, Manns MP, Korangy F, Greten TF. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol 2006; 12(20): 3275-3282 [PMID: 16718852 DOI: 10.3748/wjg.v12.i20.3275] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 58] [Article Influence: 4.1] [Reference Citation Analysis]
9 Behboudi S, Boswell S, Williams R. Cell-mediated immune responses to alpha-fetoprotein and other antigens in hepatocellular carcinoma. Liver Int. 2010;30:521-526. [PMID: 20040052 DOI: 10.1111/j.1478-3231.2009.02194.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
10 Ge L, Zhang JG, Samathanam CA, Delgado C, Tarbiyat-Boldaji M, Dan Q, Hoa N, Nguyen TV, Alipanah R, Pham JT, Sanchez R, Wepsic HT, Morgan TR, Jadus MR. Cytotoxic T cell immunity against the non-immunogenic, murine, hepatocellular carcinoma Hepa1-6 is directed towards the novel alternative form of macrophage colony stimulating factor. Cell Immunol 2009;259:117-27. [PMID: 19615673 DOI: 10.1016/j.cellimm.2009.06.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
11 Costa FF, Le Blanc K, Brodin B. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells 2007;25:707-11. [PMID: 17138959 DOI: 10.1634/stemcells.2006-0469] [Cited by in Crossref: 88] [Cited by in F6Publishing: 80] [Article Influence: 5.5] [Reference Citation Analysis]
12 Noordam L, Ge Z, Özturk H, Doukas M, Mancham S, Boor PPC, Campos Carrascosa L, Zhou G, van den Bosch TPP, Pan Q, IJzermans JNM, Bruno MJ, Sprengers D, Kwekkeboom J. Expression of Cancer Testis Antigens in Tumor-Adjacent Normal Liver Is Associated with Post-Resection Recurrence of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2499. [PMID: 34065388 DOI: 10.3390/cancers13102499] [Reference Citation Analysis]
13 Wang L, Xu Y, Luo C, Sun J, Zhang J, Lee MW, Bai A, Chen G, Frenz CM, Li Z, Huang W. MAGEA10 gene expression in non-small cell lung cancer and A549 cells, and the affinity of epitopes with the complex of HLA-A(∗)0201 alleles. Cell Immunol 2015;297:10-8. [PMID: 26058806 DOI: 10.1016/j.cellimm.2015.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Seifi-Alan M, Shamsi R, Ghafouri-Fard S. Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma. Immunotherapy 2018;10:411-21. [PMID: 29473472 DOI: 10.2217/imt-2017-0154] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
15 Smith HA, McNeel DG. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. J Immunother 2011;34:569-80. [PMID: 21904219 DOI: 10.1097/CJI.0b013e31822b5b1d] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
16 Busato D, Mossenta M, Baboci L, Di Cintio F, Toffoli G, Dal Bo M. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Rev Clin Pharmacol 2019;12:453-70. [PMID: 30907177 DOI: 10.1080/17512433.2019.1598859] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
17 Shuai Z, Leung MW, He X, Zhang W, Yang G, Leung PS, Eric Gershwin M. Adaptive immunity in the liver. Cell Mol Immunol 2016;13:354-68. [PMID: 26996069 DOI: 10.1038/cmi.2016.4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 6.5] [Reference Citation Analysis]
18 Bertino G, Demma S, Ardiri A, Proiti M, Mangia A, Gruttadauria S, Toro A, Di Carlo I, Malaguarnera G, Bertino N. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed Res Int. 2015;2015:731469. [PMID: 25893197 DOI: 10.1155/2015/731469] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
19 Liang J, Ding T, Guo ZW, Yu XJ, Hu YZ, Zheng L, Xu J. Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression. Br J Cancer. 2013;109:1031-1039. [PMID: 23868000 DOI: 10.1038/bjc.2013.390] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
20 Shimoda M, Tomimaru Y, Charpentier KP, Safran H, Carlson RI, Wands J. Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma. J Hepatol 2012;56:1129-35. [PMID: 22245894 DOI: 10.1016/j.jhep.2011.12.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
21 Gehring AJ, Ho ZZ, Tan AT, Aung MO, Lee KH, Tan KC, Lim SG, Bertoletti A. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2009;137:682-690. [PMID: 19394336 DOI: 10.1053/j.gastro.2009.04.045] [Cited by in Crossref: 106] [Cited by in F6Publishing: 109] [Article Influence: 8.2] [Reference Citation Analysis]
22 Aref AM, Hoa NT, Ge L, Agrawal A, Dacosta-Iyer M, Lambrecht N, Ouyang Y, Cornforth AN, Jadus MR. HCA519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinoma. Onco Targets Ther. 2014;7:1061-1070. [PMID: 24966688 DOI: 10.2147/ott.s61442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
23 Shirabe K, Motomura T, Muto J, Toshima T, Matono R, Mano Y, Takeishi K, Ijichi H, Harada N, Uchiyama H, Yoshizumi T, Taketomi A, Maehara Y. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management. Int J Clin Oncol 2010;15:552-8. [DOI: 10.1007/s10147-010-0131-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
24 Behboudi S, Pereira SP. Alpha-fetoprotein specific CD4 and CD8 T cell responses in patients with hepatocellular carcinoma. World J Hepatol 2010; 2(7): 256-260 [PMID: 21161007 DOI: 10.4254/wjh.v2.i7.256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
25 Janjic B, Andrade P, Wang XF, Fourcade J, Almunia C, Kudela P, Brufsky A, Jacobs S, Friedland D, Stoller R, Gillet D, Herberman RB, Kirkwood JM, Maillere B, Zarour HM. Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers. J Immunol 2006;177:2717-27. [PMID: 16888034 DOI: 10.4049/jimmunol.177.4.2717] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
26 Grunwald C, Koslowski M, Arsiray T, Dhaene K, Praet M, Victor A, Morresi-hauf A, Lindner M, Passlick B, Lehr H, Schäfer SC, Seitz G, Huber C, Sahin U, Türeci Ö. Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer. Int J Cancer 2006;118:2522-8. [DOI: 10.1002/ijc.21669] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
27 Kalathil SG, Thanavala Y. Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches. Cells 2021;10:1332. [PMID: 34071188 DOI: 10.3390/cells10061332] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Badovinac Črnjević T, Spagnoli G, Juretić A, Jakić-Razumović J, Podolski P, Šarić N. High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer. Med Oncol 2012;29:1586-91. [PMID: 22116775 DOI: 10.1007/s12032-011-0120-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
29 Greten TF, Manns MP, Korangy F. Immunotherapy of hepatocellular carcinoma. J Hepatol. 2006;45:868-878. [PMID: 17046096 DOI: 10.1016/j.jhep.2006.09.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
30 Karanikas V, Germenis A. Determinants of cancer immunotherapy success. Expert Rev Vaccines 2010;9:1363-6. [PMID: 21105772 DOI: 10.1586/erv.10.138] [Reference Citation Analysis]
31 Cheng Y, Gunasegaran B, Singh HD, Dutertre C, Loh CY, Lim JQ, Crawford JC, Lee HK, Zhang X, Lee B, Becht E, Lim WJ, Yeong J, Chan CY, Chung A, Goh BK, Chow PK, Chan JK, Ginhoux F, Tai D, Chen J, Lim SG, Zhai W, Choo SP, Newell EW. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021;54:1825-1840.e7. [DOI: 10.1016/j.immuni.2021.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Umemoto Y, Okano S, Matsumoto Y, Nakagawara H, Matono R, Yoshiya S, Yamashita Y, Yoshizumi T, Ikegami T, Soejima Y, Harada M, Aishima S, Oda Y, Shirabe K, Maehara Y. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy. J Gastroenterol. 2015;50:65-75. [PMID: 24509608 DOI: 10.1007/s00535-014-0933-3] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 6.8] [Reference Citation Analysis]
33 Fesenkova V, Sultan H, Celis E. CD4 T Cells in Antitumor Immunity. Encyclopedia of Immunobiology. Elsevier; 2016. pp. 441-50. [DOI: 10.1016/b978-0-12-374279-7.17008-0] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Mikhail S, Cosgrove D, Zeidan A. Hepatocellular carcinoma: systemic therapies and future perspectives. Expert Rev Anticancer Ther. 2014;14:1205-1218. [PMID: 25199765 DOI: 10.1586/14737140.2014.949246] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
35 Huang CJ, Anderson KA, Damasceno LM, Ritter G, Old LJ, Batt CA. Improved secretion of the cancer-testis antigen SSX2 in Pichia pastoris by deletion of its nuclear localization signal. Appl Microbiol Biotechnol 2010;86:243-53. [PMID: 19826807 DOI: 10.1007/s00253-009-2275-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
36 Wirth TC. Spontaneous and therapeutic immune responses in hepatocellular carcinoma: implications for current and future immunotherapies. Expert Rev Gastroenterol Hepatol. 2014;8:101-110. [PMID: 24410473 DOI: 10.1586/17474124.2014.862497] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
37 Jian W, Li X, Kang J, Lei Y, Bai Y, Xue Y. Antitumor effect of recombinant Mycobacterium smegmatis expressing MAGEA3 and SSX2 fusion proteins. Exp Ther Med 2018;16:2160-6. [PMID: 30186454 DOI: 10.3892/etm.2018.6425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
38 Pang Y, Zhang H, Peng J, Pang X, Yu S, Xing Q, Yu X, Gong L, Yin Y, Zhang Y, Chen W. The immunosuppressive tumor microenvironment in hepatocellular carcinoma. Cancer Immunol Immunother 2009;58:877-86. [DOI: 10.1007/s00262-008-0603-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
39 Alvarez I, Carrascal M, Canals F, Muixí L, Abián J, Jaraquemada D. Analysis of the HLA class I associated peptide repertoire in a hepatocellular carcinoma cell line reveals tumor-specific peptides as putative targets for immunotherapy. Prot Clin Appl 2007;1:286-98. [DOI: 10.1002/prca.200600388] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
40 Karanikas V, Zamanakou M, Soukou F, Kerenidi T, Gourgoulianis KI, Germenis AE. Naturally occurring tumor‐specific CD8 + T‐cell precursors in individuals with and without cancer. Immunol Cell Biol 2010;88:575-85. [DOI: 10.1038/icb.2010.8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
41 Schmidt N, Neumann-Haefelin C, Thimme R. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy. Dig Dis. 2012;30:483-491. [PMID: 23108304 DOI: 10.1159/000341697] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
42 Yao J, Caballero OL, Yung WK, Weinstein JN, Riggins GJ, Strausberg RL, Zhao Q. Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res 2014;2:371-9. [PMID: 24764584 DOI: 10.1158/2326-6066.CIR-13-0088] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]
43 Seleit I, Bakry OA, Samaka RM, Malak MA. Immunohistochemical expression of sperm-associated antigen 9 in nonmelanoma skin cancer. Am J Dermatopathol. 2015;37:38-45. [PMID: 25033008 DOI: 10.1097/dad.0000000000000126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
44 Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int. 2014;2014:203693. [PMID: 25089265 DOI: 10.1155/2014/203693] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 5.9] [Reference Citation Analysis]
45 Danilova A, Misyurin V, Novik A, Girdyuk D, Avdonkina N, Nekhaeva T, Emelyanova N, Pipia N, Misyurin A, Baldueva I. Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells. Clin Sarcoma Res 2020;10:3. [PMID: 32042403 DOI: 10.1186/s13569-020-0125-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
46 Suzuki S, Sasajima K, Sato Y, Watanabe H, Matsutani T, Iida S, Hosone M, Tsukui T, Maeda S, Shimizu K. MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer. Br J Cancer. 2008;99:350-356. [PMID: 18594524 DOI: 10.1038/sj.bjc.6604476] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
47 Huang TT, Yen MC, Lin CC, Weng TY, Chen YL, Lin CM, Lai MD. Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer. Cancer Sci 2011;102:2214-20. [PMID: 21899659 DOI: 10.1111/j.1349-7006.2011.02094.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
48 Smith HA, McNeel DG. The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin Dev Immunol 2010;2010:150591. [PMID: 20981248 DOI: 10.1155/2010/150591] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 4.6] [Reference Citation Analysis]
49 Akazawa Y, Suzuki T, Yoshikawa T, Mizuno S, Nakamoto Y, Nakatsura T. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World J Meta-Anal 2019; 7(3): 80-95 [DOI: 10.13105/wjma.v7.i3.80] [Reference Citation Analysis]
50 Dashti S, Taherian-Esfahani Z. Cellular immune responses against cancer-germline genes in cancers. Hum Antibodies 2020;28:57-64. [PMID: 31356200 DOI: 10.3233/HAB-190392] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Bricard G, Cesson V, Devevre E, Bouzourene H, Barbey C, Rufer N, Im JS, Alves PM, Martinet O, Halkic N. Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol. 2009;182:5140-5151. [PMID: 19342695 DOI: 10.4049/jimmunol.0711086] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 5.6] [Reference Citation Analysis]
52 Huang CJ, Chen RH, Vannelli T, Lee F, Ritter E, Ritter G, Old LJ, Batt CA. Expression and purification of the cancer antigen SSX2: a potential cancer vaccine. Protein Expr Purif 2007;56:212-9. [PMID: 17931884 DOI: 10.1016/j.pep.2007.07.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
53 Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015;62:1420-1429. [PMID: 25733155 DOI: 10.1016/j.jhep.2015.02.038] [Cited by in Crossref: 139] [Cited by in F6Publishing: 151] [Article Influence: 19.9] [Reference Citation Analysis]
54 Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T. Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenterol 2015; 21(36): 10314-10326 [PMID: 26420958 DOI: 10.3748/wjg.v21.i36.10314] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
55 Shirabe K, Motomura T, Muto J, Toshima T, Matono R, Mano Y, Takeishi K, Ijichi H, Harada N, Uchiyama H. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management. Int J Clin Oncol. 2010;15:552-558. [PMID: 20963618 DOI: 10.1007/s10147-010-0131-0.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Õunap K, Kurg K, Võsa L, Maiväli Ü, Teras M, Planken A, Ustav M, Kurg R. Antibody response against cancer-testis antigens MAGEA4 and MAGEA10 in patients with melanoma. Oncol Lett 2018;16:211-8. [PMID: 29928403 DOI: 10.3892/ol.2018.8684] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Raskin S, Van Pelt S, Toner K, Balakrishnan PB, Dave H, Bollard CM, Yvon E. Novel TCR-like CAR-T cells targeting an HLA∗0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia. Mol Ther Methods Clin Dev 2021;23:296-306. [PMID: 34729377 DOI: 10.1016/j.omtm.2021.09.008] [Reference Citation Analysis]
58 Ji J, Chen J, Wang A, Zhang W, Ju H, Liu Y, Li L. KK-LC-1 may be an effective prognostic biomarker for gastric cancer. BMC Cancer 2021;21:267. [PMID: 33711953 DOI: 10.1186/s12885-021-07974-7] [Reference Citation Analysis]
59 Korangy F, Höchst B, Manns MP, Greten TF. Immunotherapy of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2010;4:345-53. [PMID: 20528121 DOI: 10.1586/egh.10.18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
60 Aerts M, Benteyn D, Van Vlierberghe H, Thielemans K, Reynaert H. Current status and perspectives of immune-based therapies for hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 253-261 [PMID: 26755874 DOI: 10.3748/wjg.v22.i1.253] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
61 Buonaguro L; HEPAVAC Consortium. New vaccination strategies in liver cancer. Cytokine Growth Factor Rev 2017;36:125-9. [PMID: 28688773 DOI: 10.1016/j.cytogfr.2017.06.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
62 Tomimaru Y, Mishra S, Safran H, Charpentier KP, Martin W, De Groot AS, Gregory SH, Wands JR. Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma. Vaccine 2015;33:1256-66. [PMID: 25629522 DOI: 10.1016/j.vaccine.2015.01.037] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
63 Schultz-Thater E, Piscuoglio S, Iezzi G, Le Magnen C, Zajac P, Carafa V, Terracciano L, Tornillo L, Spagnoli GC. MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies. Int J Cancer 2011;129:1137-48. [PMID: 21710496 DOI: 10.1002/ijc.25777] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]